Primary mediastinal B-cell lymphoma and mediastinal gray zone lymphoma: do they require a unique therapeutic approach?
about
Novel drug targets for personalized precision medicine in relapsed/refractory diffuse large B-cell lymphoma: a comprehensive reviewMature aggressive B-cell lymphoma across age groups - molecular advances and therapeutic implications.Composite Lymphoma: Opposite Ends of Spectrum Meet.Genomic Landscape of Primary Mediastinal B-Cell Lymphoma Cell Lines.[Primary mediastinal large B-cell lymphoma in women: about five cases]Mediastinal gray zone lymphoma: clinico-pathological characteristics and outcomes of 99 patients from the Lymphoma Study Association.Recurrent mutations of the exportin 1 gene (XPO1) and their impact on selective inhibitor of nuclear export compounds sensitivity in primary mediastinal B-cell lymphoma.Childhood, adolescent and young adult non-Hodgkin lymphoma: state of the science.How I manage patients with grey zone lymphoma.PD-1-PD-L1 immune-checkpoint blockade in B-cell lymphomas.XPO1 in B cell hematological malignancies: from recurrent somatic mutations to targeted therapy.Improved survival with combined modality therapy in the modern era for primary mediastinal B-cell lymphoma.Axicabtagene ciloleucel, a first-in-class CAR T cell therapy for aggressive NHL.Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma.Favorable response of relapsed/refractory gray-zone lymphoma to brentuximab vedotin.Role of Bruton's tyrosine kinase in B cells and malignancies.
P2860
Q27304386-9EACE582-FE8C-42E4-9BDA-0BD72F51776DQ30240133-03FAB756-66C9-4480-B71D-647BB77456BCQ33168244-147D3427-6833-44B1-9F63-8BAC7620C3EEQ35850206-AC19AAE4-7DB1-494A-BD05-F6DBD1DCF7C4Q37354614-6060A85A-EE6E-423C-A46F-C8362E6CBCB6Q37555826-38E1900D-642D-4D82-B033-A927081B29E1Q38764010-7B876B37-6868-46DE-A02D-7ED018527670Q38822525-48606EE3-0D20-4810-94FE-DF1B72A8999CQ38865120-81B205A3-7C7C-4D7E-80AD-475F2F714BEBQ38996724-CF4160B6-1642-48ED-9405-A17B8C1380B4Q39135290-326D6478-E491-4B70-9F44-4FD0FB8A3FC3Q40017480-3C045ED4-AA22-4D69-B1F9-DAA6729A29C6Q46082373-34EBFD48-BE56-4616-90CA-E776E3744E5BQ46438521-6ECAE684-3EB1-4A28-BDFE-A9F6E0AAE50DQ48190434-3BF99706-9CB3-41D1-85FF-42A2D82ED57EQ49888075-50A91497-5B23-41FF-8ADE-6DAEADA97F5D
P2860
Primary mediastinal B-cell lymphoma and mediastinal gray zone lymphoma: do they require a unique therapeutic approach?
description
2014 nî lūn-bûn
@nan
2014 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Primary mediastinal B-cell lym ...... a unique therapeutic approach?
@ast
Primary mediastinal B-cell lym ...... a unique therapeutic approach?
@en
Primary mediastinal B-cell lym ...... a unique therapeutic approach?
@nl
type
label
Primary mediastinal B-cell lym ...... a unique therapeutic approach?
@ast
Primary mediastinal B-cell lym ...... a unique therapeutic approach?
@en
Primary mediastinal B-cell lym ...... a unique therapeutic approach?
@nl
prefLabel
Primary mediastinal B-cell lym ...... a unique therapeutic approach?
@ast
Primary mediastinal B-cell lym ...... a unique therapeutic approach?
@en
Primary mediastinal B-cell lym ...... a unique therapeutic approach?
@nl
P2860
P1433
P1476
Primary mediastinal B-cell lym ...... a unique therapeutic approach?
@en
P2093
Kieron Dunleavy
Wyndham H Wilson
P2860
P356
10.1182/BLOOD-2014-05-575092
P407
P577
2014-12-11T00:00:00Z